Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML

27 Oct 2023

Abstract excerpt

KMT2A-rearranged (KMT2A-R) is an aggressive and chemo-refractory acute leukemia which mostly affects children. Transcriptomics-based characterization and chemical interrogation identified kinases as key drivers of survival and drug resistance in KMT2A-R leukemia. In contrast, the contribution and regulation of phosphatases is unknown. In this study we uncover the essential role and underlying mechanisms of SET,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Histone Deacetylase Inhibitors Research
Share to Multiple Myeloma Research and Treatments
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37891368
DOI: 10.1038/s41388-023-02840-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AMLPMID 37891368Read ↗

SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.Semantic proximity Read ↗

The nuclear oncoprotein SET is necessary for MLL/KMT2A binding and transcriptional elongationSemantic proximity Read ↗

Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemiaSemantic proximity Read ↗

Immunoproteasome function maintains oncogenic gene expression in KMT2A-complex driven leukemia.Semantic proximity Read ↗

Acute Myeloid Leukemias with Alterations of Lysine Methyltransferase 2A (KMT2A): Recent Therapeutic DevelopmentsSemantic proximity Read ↗

Insights into KMT2A rearrangements in acute myeloid leukemia: from molecular characteristics to targeted therapiesSemantic proximity Read ↗

KMT2D Deficiency Promotes Myeloid Leukemias which Is Vulnerable to Ribosome Biogenesis InhibitionSemantic proximity Read ↗

PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemiaSemantic proximity Read ↗

Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes.Semantic proximity Read ↗

MYST Acetyltransferases Interact with SETBP1 and Are a Targetable Therapeutic Vulnerability in SETBP1-Mutant Leukemia.Semantic proximity Read ↗

Role of SHP2 phosphatase in KIT-induced transformation: identification of SHP2 as a druggable target in diseases involving oncogenic KIT.Semantic proximity Read ↗

Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.